Tools
ToolsGc, Vijay S., Franklin, Donna, Whitty, Jennifer A., Dalziel, Stuart R., Babl, Franz E., Schlapbach, Luregn J., Fraser, John F., Craig, Simon, Neutze, Jocelyn, Oakley, Ed and Schibler, Andreas (2020) First line oxygen therapy with high-flow in bronchiolitis is not cost saving for the health service. Archives of Disease in Childhood, 105 (10). pp. 975-980. ISSN 0003-9888
Preview |
PDF (Accepted_Manuscript)
- Accepted Version
Download (189kB) | Preview |
Preview |
PDF (Fig 1 revised)
- Accepted Version
Download (427kB) | Preview |
Abstract
Background Bronchiolitis is the most common reason for hospital admission in infants. High-flow oxygen therapy has emerged as a new treatment; however, the cost-effectiveness of using it as first-line therapy is unknown. Objective To compare the cost of providing high-flow therapy as a first-line therapy compared with rescue therapy after failure of standard oxygen in the management of bronchiolitis. Methods A within-trial economic evaluation from the health service perspective using data from a multicentre randomised controlled trial for hypoxic infants (≤12 months) admitted to hospital with bronchiolitis in Australia and New Zealand. Intervention costs, length of hospital and intensive care stay and associated costs were compared for infants who received first-line treatment with high-flow therapy (early high-flow, n=739) or for infants who received standard oxygen and optional rescue high-flow (rescue high-flow, n=733). Costs were applied using Australian costing sources and are reported in 2016–2017 AU$. Results The incremental cost to avoid one treatment failure was AU$1778 (95% credible interval (CrI) 207 to 7096). Mean cost of bronchiolitis treatment including intervention costs and costs associated with length of stay was AU$420 (95% CrI −176 to 1002) higher per infant in the early high-flow group compared with the rescue high-flow group. There was an 8% (95% CrI 7.5 to 8.6) likelihood of the early high-flow oxygen therapy being cost saving. Conclusions The use of high-flow oxygen as initial therapy for respiratory failure in infants with bronchiolitis is unlikely to be cost saving to the health system, compared with standard oxygen therapy with rescue high-flow.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | costing,health economics,intensive care,respiratory,pediatrics, perinatology, and child health ,/dk/atira/pure/subjectarea/asjc/2700/2735 |
| Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
| UEA Research Groups: | Faculty of Medicine and Health Sciences > Research Groups > Public Health and Health Services Research (former - to 2023) Faculty of Medicine and Health Sciences > Research Groups > Health Economics Faculty of Medicine and Health Sciences > Research Groups > Health Services and Primary Care Faculty of Medicine and Health Sciences > Research Groups > Respiratory and Airways Group Faculty of Medicine and Health Sciences > Research Centres > Norwich Institute for Healthy Aging |
| Related URLs: | |
| Depositing User: | LivePure Connector |
| Date Deposited: | 03 Apr 2020 00:45 |
| Last Modified: | 28 Mar 2025 09:46 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/74695 |
| DOI: | 10.1136/archdischild-2019-318427 |
Downloads
Downloads per month over past year
Actions (login required)
 |
View Item |